<?xml version="1.0" encoding="UTF-8"?>
<ref id="B3-ijerph-17-04951">
 <label>3.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Bourliere</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Gane</surname>
    <given-names>E.J.</given-names>
   </name>
   <name>
    <surname>Jacobson</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Gordon</surname>
    <given-names>S.C.</given-names>
   </name>
   <name>
    <surname>Sulkowski</surname>
    <given-names>M.S.</given-names>
   </name>
   <name>
    <surname>McNabb</surname>
    <given-names>B.L.</given-names>
   </name>
   <name>
    <surname>Reddy</surname>
    <given-names>K.R.</given-names>
   </name>
  </person-group>
  <article-title>Long-term follow up of patients with chronic HCV and no or minimal fibrosis shows low risk for liver-related morbidity and mortality after achieving SVR with DAA-based therapy: Results from the Gilead SVR registry</article-title>
  <source>Hepatology</source>
  <year>2017</year>
  <volume>66</volume>
  <issue>Suppl. 1</issue>
  <fpage>518A</fpage>
  <lpage>519A</lpage>
  <pub-id pub-id-type="pmid">28390159</pub-id>
 </element-citation>
</ref>
